Healthcare
Live Price
Offline$25.60
+0.59% today
1Y Change
+63.52%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pulse Biosciences, Inc. (PLSE) is a Healthcare stock with a market cap of $1.42B and listed on NASDAQ. The stock last traded around $25.60 and up 63.5% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -17.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -17.4%, free cash flow -49.3% with operating margin -21982.6% and ROIC -85.7%. Valuation already assumes a fairly strong business story at price/sales 4046.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PLSE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLSE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLSE Max Drawdown
-36.51%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLSE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
+102.6% YoY
FY Net Income
-$63.7M
-8.8% YoY
Free Cash Flow
-$54.5M
-15.0% YoY
Revenue Growth
+0.0%
EPS Growth
-17.4%
Gross Margin
-204.3%
Net Margin
-20794.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 350K | 0 | 0 | 700K | 1M |
| Gross Profit | -1M | 0 | -1M | -11M | -550K |
| Operating Income | -77M | -56M | -44M | -58M | -63M |
| EBITDA | -72M | -55M | -42M | -57M | -62M |
| Net Income | -73M | -54M | -42M | -59M | -64M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 81M | 118M | 44M | 61M | 29M |
| Total Assets | 96M | 132M | 59M | 78M | 54M |
| Total Liabilities | 15M | 18M | 15M | 80M | 19M |
| Shareholder Equity | 81M | 115M | 44M | -2M | 36M |
| Total Debt | 8M | 9M | 9M | 76M | 11M |
| Net Debt | -73M | -109M | -35M | 15M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
-15.1% YoY
Capital Expenditures
437K
-9.0% YoY
Free Cash Flow
55M
-15.0% YoY
Key ratios
Gross Margin
-204.3%
Operating Margin
-21982.6%
Net Margin
-20794.6%
ROE
-73.5%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.